Search hospitals

>

Nevada

>

Las Vegas

University Medical Center of Southern Nevada

Claim this profile

Las Vegas, Nevada 89102

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Lung Cancer

Conducts research for Breast cancer

Conducts research for Brain Tumor

361 reported clinical trials

3 medical researchers

Photo of University Medical Center of Southern Nevada in Las VegasPhoto of University Medical Center of Southern Nevada in Las VegasPhoto of University Medical Center of Southern Nevada in Las Vegas

Summary

University Medical Center of Southern Nevada is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Brain Tumor and other specialties. University Medical Center of Southern Nevada is involved with conducting 361 clinical trials across 530 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Chowdhury Ahsan, MD.

Area of expertise

1

Breast Cancer

Global Leader

University Medical Center of Southern Nevada has run 53 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
Stage IV
2

Cancer

Global Leader

University Medical Center of Southern Nevada has run 53 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at University Medical Center of Southern Nevada

Bladder Cancer

Breast Cancer

Esophageal cancer

Lung Cancer

Kidney Cancer

Bladder Carcinoma

Breast cancer

Cancer

Gastric cancer

Testicular cancer

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University Medical Center of Southern Nevada?

Where is University Medical Center of Southern Nevada located?

Who should I call to ask about financial aid or insurance network?

What insurance does University Medical Center of Southern Nevada accept?

What awards or recognition has University Medical Center of Southern Nevada received?